REGENXBIO Inc. (NASDAQ: RGNX) is a Healthcare company (Biotechnology) with a market capitalization of $479M. The Maz Rating grades it against the other companies in its sector.
REGENXBIO Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.24, REGENXBIO Inc. trades at 3.1x sales and 3.2x book value. Over the last twelve months it generated about $155M of revenue and a net loss of $214M. It runs a gross margin of 87.5%, an operating margin of -95.7% and a net margin of -113.9%. It shows return on equity of -204.0%, return on invested capital of -36.4% and a free cash flow yield of -32.3%. On the balance sheet: a debt-to-equity ratio of 0.45 and a current ratio of 4.74. Over the past 52 weeks the share price ranged from $5.46 to $16.19, with a beta of 0.93.
REGENXBIO Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 1 Strong Buy, 12 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, REGENXBIO Inc. (RGNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 56.2% / 30% · Interest income / Revenue 24.8% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 56.2% / 33% · Receivables / Mkt Cap (36m) 12.5% / 49% · Interest income / Revenue 24.8% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 56.2% / 33.33% · Receivables / Mkt Cap (24m) 12.5% / 33.33% · Interest income / Revenue 24.8% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 11.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 44.7% / 33.33% · Receivables / Avg Assets (4Q) 12.2% / 33.33% · Interest income / Revenue 24.8% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 53.9% / 33.33% · (Cash+Recv) / Total Assets 65.9% / 33.33% · Interest income / Revenue 24.8% / 5% | Fail |
No. As of September 2026, REGENXBIO Inc. (RGNX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. REGENXBIO Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 24.8% of each dividend: REGENXBIO Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.